In this industry report by Global Business Reports (GBR), you can find content featuring CEO Alan Petro, including an interview.
On page 83 (PDF page 42), you will find insight by Alan on why Blow-Fill-Seal (BFS) technology is being adopted more widely today.
On page 85 of the report (PDF page 43), you will find the interview featuring Alan.
To view the complete report, please click the following link: CPhI – Global Business Reports (GBR) – United States Pharmaceuticals and Biopharmaceuticals 2021
For your convenience, you can find Alan’s excerpts from the report below.
In this industry report by Global Business Reports (GBR), you can find content featuring CEO Alan Petro, including an interview.
On page 83 (PDF page 42), you will find insight by Alan on why Blow-Fill-Seal (BFS) technology is being adopted more widely today.
On page 85 of the report (PDF page 43), you will find the interview featuring Alan.
Can you provide an overview of New Vision Pharmaceuticals?
New Vision Pharmaceuticals is focused on providing exact dose Blow-Fill-Seal technology for a wide variety of formulations and products. We provide confidence and quality to the Rx, OTC, diagnostic reagent, cosmetic and dietary supplement markets. We help clients make their product through reformulation, more economical production methods, better packaging and improved customer presentation.
What are the underlying trends diving the adoption of Blow-Fill-Seal technology?
There are a number of reasons why Blow-Fill-Seal technology is being adopted more widely. Drugs are becoming more potent and doses are getting smaller. Therefore, the doses must be more precise. At the same time, the global population is getting older and drug packaging must become more patient-centric and easier to use. Especially with seniors, the packaging must be easy to use to allow treatment in the home. Blow-Fill-Seal packaging is ideally suited to meet these needs. This need has been especially important as we have transitioned through a variety of lockdowns that limit access to the traditional points of medical care.
Blow-Fill-Seal technology is recognized by USP 1116 as an advanced aseptic process that allows for superior microbiological control, precise filling accuracy, exceptional process and product reliability, the capacity to apply inert cover gases and adapts to a wide variety of formulations. It has concomitant advantages of being significantly lighter in weight than glass containers, unbreakable in transit and not subject to spoiling. These factors result in lower shipping costs and fewer potential end-to-end quality concerns. It has the additional benefit of being counterfeit resistant which enhances public confidence and overall safety.
While Blow-Fill-Seal technology has been long been established in Europe, its introduction in the US and Asia is accelerating. Even though the production equipment is costly to purchase and maintain, it provides excellent economy of scale through its high production rate, exquisite quality and low labor requirements. It enables highly automated, precision manufacturing which delivers quality products in a very cost effective manner.
How does Blow-Fill-Seal boost adherence?
One of the unique aspects of Blow-Fill-Seal is the single use doses that in many cases are sterile. This enables us to reduce the issues of overdosing in pediatric cases.
What are the most important areas of growth and investment for New Vision?
Today we are adding high volume Blow-Fill-Seal capacity to meet customer needs. As we speak, another machine is being prepared for shipment from Germany and will be fully operational later this year. This will bring to six the number of BFS machines in house. We anticipate making investments in the support systems, including enhancing track and trace to support evolving regulatory needs.
We are also focusing on developing an empowered and highly flexible organization that can bring client ideas to fruition more quickly. This means that concepts can move rapidly into phase 2 production and later easily transition to phase 3 and ultimately commercial manufacturing. We believe that there are several drivers for increased application and acceptance of Blow-Fill-Seal technology. These trends suggest that New Vision Pharmaceuticals is well positioned for market growth.
What are the primary goals of the company moving forward?
Our primary goals are to fully utilize the significant investment that we have made over the last several years in the facility and staff. We have an excellent team who have demonstrated the ability to give clients the quality and schedule reliability they need to deliver innovative products. In the coming years we want to do the same, but with quicker project schedules and the ability to assist if and when the next public health issue presents itself. Through our capabilities, we can quickly bring generics to market, reduce our country’s dependence on offshore drug manufacturing and deliver products with enhanced anti-counterfeiting features.
Source: https://www.gbreports.com/interview/alan-petro
Can you provide an overview of New Vision Pharmaceuticals? New Vision Pharmaceuticals is focused on providing exact dose Blow-Fill-Seal technology for a wide variety of formulations and products. We provide confidence and quality to the Rx, OTC, diagnostic reagent, cosmetic and dietary supplement markets. We help clients make their product…
Single-use Reagents, Made with Advanced Blow-Fill-Seal Technology, Answer Need for Rapid Point-of-Care and Home COVID-19 Test Kits
TAMARAC, Fla. (April 7, 2021) — New Vision Pharmaceuticals, a contract pharmaceutical development and manufacturing company specializing in blow-fill-seal packaging, has announced the availability of single-use diagnostic reagents for use in antibody and antigen COVID-19 test kits. The reagents, which are produced and packaged using innovative Blow-Fill-Seal (BFS) technology, come in convenient 0.5 milliliter plastic single-use vials for easy use in the testing process. When applied to test materials, the reagents help facilitate highly accurate results within minutes.
“Given emerging, more transmissible COVID-19 variants, rapid and reliable testing is more critical than ever to public health and ending the pandemic,” said Alan Petro, CEO of New Vision Pharmaceuticals. “Our reagents, which are safe and simple to handle, are used in test kits administered in both home and healthcare settings. We work closely with our test kit clients to formulate and produce these convenient reagent vials. Made with BFS technology to the most precise specifications, they can contain different types of reagents for use in diagnosing a range of conditions, in addition to COVID-19.”
New Vision Pharmaceuticals’ COVID-19 reagent vials are produced at its state-of-the-art 165,000 square foot pharmaceutical manufacturing facility. This facility also makes products in traditional packaging in addition to those made with BFS technology. The company has the capacity to produce 50 million vials per month and can quickly ramp up production as it recently did for a provider of high-quality diagnostic tests to aid in the detection and diagnosis of diseases.
“With this client, our team was able to go from initial discussions to formulation, BFS production and delivery of these reagents in less than four weeks,” said Petro.
We recognize that product priorities can quickly change in the pharmaceutical market, and our goal is to be as flexible and accommodating as possible for all our clients so they can meet public health and other challenges.
Blow-Fill-Seal (BFS) is the most advanced technology available for manufacturing premeasured single-dose containers. This technology is an automated process by which containers are formed, filled and sealed in a continuous operation without human intervention. BFS technology can be used to manufacture any liquid dosage and is widely considered to be the superior form of aseptic processing by a range of pharmaceutical regulatory agencies.
New Vision Pharmaceuticals, a company recently formed under an investment arm of Morgan Stanley, brings advanced technology and production facilities to the dynamic contract development and manufacturing organization (CDMO) market, along with top talent and an experienced management team. This team is strongly attuned to the diagnostic testing market and is looking for major advancements in that area for the future.
New Vision Pharmaceuticals is a full-service, FDA-registered contract development and manufacturing company that provides innovative solutions through blow-fill-seal (BFS), fill-seal (FS) and traditional packaging for liquid and semi-solid products in a breadth of industries. These industries include pharmaceutical, diagnostic reagent, dietary supplement and a multitude of other applications. With headquarters and state-of-the-art manufacturing facilities located in Tamarac, Fla., near the international logistics hub of Miami, New Vision Pharmaceuticals provides an economical avenue to deliver products at scale, quickly, safely and effectively—in the exact formulation you need from single dose to traditional packaging. New Vision Pharmaceuticals prides itself on working directly with clients as a true partner to deliver tailor-made products for their individual applications, providing peace of mind through excellence in quality, reliability and service. Visit newvisionpharmaceuticals.com for more information on solutions for your product development and packaging needs, and follow us on Twitter at @NewVisionPharm1, LinkedIn and Facebook.
Media Contact:
Jan Sisko
Carabiner Communications
O: 678.461.7438
M: 678.591.2022
jsisko@carabinercomms.com
New Vision Pharmaceuticals, a contract pharmaceutical development and manufacturing company specializing in blow-fill-seal packaging, has announced the availability of single-use diagnostic reagents for use in antibody and antigen COVID-19 test kits…
By Alan Petro
Recently acquired by an investment arm of Morgan Stanley, New Vision Pharmaceuticals is a full-service, FDA-registered CDMO. We provide innovative solutions through blow-fill-seal (BFS), fill-seal, stick pack and traditional packaging for liquid and semi-solid products in a breadth of industries. At our state-of-the-art 165,000 square foot pharmaceutical manufacturing facility, we can both formulate and fulfill pharmaceuticals, diagnostic reagents, dietary supplements and a multitude of other products for domestic and global markets.
New Vision’s acquisition represents a strategic investment by our owner, Morgan Stanley, in an area with significant value creation potential given the CDMO market’s growth and excellent customer acceptance around the world. For customers, both domestic and international, the synergies between New Vision and Morgan Stanley allow us to better serve you through enhanced technology investment and broader market reach.
With access to new capital from the acquisition, New Vision is adding production options and capabilities to meet your unique needs faster and to deliver innovative products to your specifications. As an example, we’re investing in your future needs with a new BFS production line arriving soon from Germany to deliver increased volume, economy and quality to our customers.
We’ve also brought in new talent throughout the organization to further our growth, including a management team that’s strongly attuned to the pharmaceutical and diagnostic testing markets and is looking for major advancements in those areas. Our talent includes seasoned professionals who understand the needs of our customers like the newest member of our management team, Chief Commercial Officer John Kelly. John brings a wealth of experience in the CDMO industry, and many in the industry have worked successfully with him in the past.
To expand our reach and product offerings, New Vision Pharmaceuticals has also invested in top R&D talent in addition to new technology. Through this talent and capability, we can develop new products or enhance current products.
We can also scale quickly to meet shifting market demands, as we recently did for a provider of high-quality diagnostic tests to aid in the detection and diagnosis of COVID-19. With this client, our team was able to go from initial discussions to formulation, BFS production and delivery of these reagents in less than four weeks. We recognize that product priorities can quickly change in the pharmaceutical market, as during the pandemic, and our goal is to be as flexible and accommodating as possible for all our clients so they can meet these challenges.
The combination of additional capital, skilled talent and focus on key markets will allow New Vision Pharmaceuticals to achieve its long-term vision of becoming a preeminent CDMO. We plan to continue expanding our prescription, over-the-counter, diagnostic reagent, and dietary supplement product lines. This is enabled by our focus on quality, reliability and on-time performance.
We truly look forward to meeting your future CDMO needs as we grow together and improve the lives of consumers who use our products.
There’s an exciting entrant into the contract development and manufacturing organization (CDMO) market: New Vision Pharmaceuticals…
We’re changing how pharmaceutical, health, wellness and a multitude of other products are developed and packaged. Tell us your challenge then let us deliver a tailor-made solution for your application.
10200 NW 67th Street Tamarac, Fl 33321
Main: +1 (954) 721-5000 | Fax: +1 (954) 721-5001
info@newvisionpharma.com
© 2021 New Vision Pharmaceuticals. All rights reserved.
